PCR carryover occurs when previously generated amplicons contaminate a later reaction. A dUTP/uracil-DNA glycosylase strategy replaces some or all dTTP with dUTP during amplification so that uracil-containing carryover products can be selectively damaged before the next amplification. Native genomic DNA generally lacks the deliberately incorporated uracil pattern used by this workflow.
UDG removes uracil from DNA to create abasic sites. A pre-incubation allows contaminating uracil-containing amplicons to be processed before thermal cycling. Heat-labile UDG can simplify inactivation at moderate temperature, whereas standard UDG may require careful workflow design to prevent unwanted activity. The polymerase must efficiently accept the chosen dUTP composition.
Creative Enzymes supplies E. coli UDG, heat-labile UDG, glycerol-free heat-labile UDG, and dUTP for carryover-control development.
Figure 1. Uracil DNA glycosylase-supplemented loop-mediated isothermal amplification. (Fallahi et al., 2018)
UDG removes uracil from DNA to create abasic sites. A pre-incubation allows contaminating uracil-containing amplicons to be processed before thermal cycling. Heat-labile UDG can simplify inactivation at moderate temperature, whereas standard UDG may require careful workflow design to prevent unwanted activity. The polymerase must efficiently accept the chosen dUTP composition.
PCR carryover occurs when previously generated amplicons contaminate a later reaction. A dUTP/uracil-DNA glycosylase strategy replaces some or all dTTP with dUTP during amplification so that uracil-containing carryover products can be selectively damaged before the next amplification. Native genomic DNA generally lacks the deliberately incorporated uracil pattern used by this workflow. The relevant enzyme must be evaluated in the complete sample-to-result workflow because cofactors, carryover from upstream steps, target abundance, temperature, reaction time, and detection chemistry can change apparent performance.
Product selection should begin with the complete reaction and workflow rather than an isolated activity value. The following components represent practical roles that may be evaluated for UDG/dUTP carryover prevention enzymes development.
| Enzyme or Reagent | Role in the Workflow | Representative Product or Support | Selection Considerations |
|---|---|---|---|
| Standard UDG | Pre-PCR degradation of uracil-containing carryover DNA | E. coli UDG | Incubation, inactivation, polymerase timing and storage |
| Heat-labile UDG | Carryover control with lower-temperature inactivation | Heat-labile UDG | Residual activity, inactivation temperature and assay program |
| Glycerol-free heat-labile UDG | Dry-format and low-glycerol formulation development | Glycerol-free heat-labile UDG | Drying recovery, reconstitution and shelf-life |
| dUTP | Incorporation into new amplicons | dUTP Solution | dUTP:dTTP ratio, polymerase acceptance and amplification efficiency |
| Compatible polymerase | Generation of uracil-containing amplicons | Selected Taq/hot-start polymerase | dUTP tolerance, hot-start profile, specificity and multiplex performance |
Figure 2. Schematic illustration of the principle of AUDG-LAMP assay for preventing carryover contamination A total of two stages are required by AUDG-LAMP assay for preventing carryover contamination. (Wang et al., 2018)
Carryover control works only when new amplicons contain uracil and the next reaction exposes them to active UDG before amplification. It does not remove ordinary genomic DNA, synthetic DNA lacking uracil, environmental target organisms, or contamination introduced after UDG has been inactivated. Physical separation of pre- and post-amplification work, unidirectional workflow, closed-tube detection, cleaning, aerosol-resistant tips, and environmental monitoring remain important.
The dUTP fraction must be defined. Complete replacement of dTTP can maximize susceptibility of amplicons to UDG but may affect some polymerases or assays. Partial substitution may preserve performance while still introducing multiple uracils, but carryover susceptibility then depends on amplicon composition and length. Primers and probes are generally synthesized with thymidine unless deliberately designed otherwise, so they are not automatically removed by UDG.
Key factors to define and verify include:
These factors should be studied together because improving one response can shift background, recovery, reaction time, or compatibility elsewhere in the workflow. Final acceptance criteria should reflect the intended reagent configuration and sample process.
Standard E. coli UDG is active during the pre-incubation and may retain activity unless the thermal protocol and formulation provide adequate control. Heat-labile UDG is designed for easier thermal inactivation, which can reduce the risk of continued activity during amplification. However, inactivation temperature and time must be verified in the final master mix because salts, stabilizers, enzyme concentration, and heating rate can change residual activity.
For RT-qPCR, UDG should not be assumed to act on RNA; its purpose is removal of uracil-containing DNA carryover. The pre-incubation must also preserve RNA and reverse-transcriptase performance. For isothermal amplification, the absence of a high-temperature denaturation step can complicate UDG inactivation. A staged temperature program, heat-labile enzyme, or physical separation may be required. One-pot compatibility should be demonstrated rather than inferred from PCR use.
Key factors to define and verify include:
These factors should be studied together because improving one response can shift background, recovery, reaction time, or compatibility elsewhere in the workflow. Final acceptance criteria should reflect the intended reagent configuration and sample process.
A useful challenge material is a representative uracil-containing amplicon generated with the intended nucleotide composition. Serial concentrations can model minor through severe contamination. The study should compare UDG-containing and UDG-free reactions while confirming that authentic target recovery is maintained. Non-uracil DNA controls demonstrate specificity of the control strategy and help reveal general inhibition.
No-template controls alone do not show the capacity of the system to neutralize carryover. Conversely, complete removal of a small spike does not establish protection against an unrealistic high-load event. Acceptance criteria should specify the challenge concentration, pre-incubation, thermal program, replicate number, target recovery, and residual UDG assessment. Stability studies should repeat both positive amplification and carryover neutralization because the polymerase and UDG may degrade at different rates.
Key factors to define and verify include:
These factors should be studied together because improving one response can shift background, recovery, reaction time, or compatibility elsewhere in the workflow. Final acceptance criteria should reflect the intended reagent configuration and sample process.
Because UDG creates abasic sites in uracil-containing DNA, the treated carryover product is rendered unsuitable for efficient amplification under the intended conditions. The uracil distribution depends on amplicon sequence and nucleotide formulation. If amplified material must be retained for cloning, sequencing, or another downstream process, the consequences of dUTP incorporation should be assessed in advance. Laboratories should also avoid assuming that UDG treatment makes it safe to open high-copy reactions; post-amplification containment remains the more reliable way to limit environmental loading.
Document the following elements:
Evaluation should include:
Acceptance criteria should be tied to the intended sample-to-result workflow and verified using appropriate controls.
Evaluation should include:
Acceptance criteria should be tied to the intended sample-to-result workflow and verified using appropriate controls.
Evaluation should include:
Acceptance criteria should be tied to the intended sample-to-result workflow and verified using appropriate controls.
Evaluation should include:
Acceptance criteria should be tied to the intended sample-to-result workflow and verified using appropriate controls.
Potential risks to evaluate include:
Relevant challenge levels and acceptance criteria depend on the intended use, sample matrix, reaction format, instrument, and decision threshold. Performance should be established with the final formulation rather than inferred from individual-component specifications.
Troubleshooting UDG/dUTP carryover prevention enzymes is most efficient when the workflow is divided into sample preparation, enzyme reaction, signal generation, and result interpretation. A positive control and a negative control are necessary, but they may not identify which module failed. Orthogonal measurements and module-specific controls should be selected before changing multiple reagents at once.
| Observation | Possible Causes | Focused Checks |
|---|---|---|
| Carryover challenge remains positive | Insufficient UDG exposure or low uracil content | Verify challenge composition, pre-incubation, enzyme level, and inactivation program |
| Authentic target recovery decreases | UDG carryover, polymerase incompatibility, or nucleotide imbalance | Compare UDG-free reactions and titrate dUTP composition and inactivation |
| PCR works but isothermal assay fails | UDG cannot be adequately staged or inactivated | Evaluate a heat-labile enzyme, staged temperature step, or separated workflow |
| Protection declines during storage | UDG degrades faster than the polymerase | Repeat carryover challenge and target amplification throughout stability studies |
A single successful repeat does not confirm the cause of a failure. Once a likely factor is identified, the proposed correction should be challenged across target levels, representative matrices, reagent lots, instruments or devices, operators, and relevant environmental conditions. The final procedure should define valid controls, acceptance criteria, and actions for invalid runs.
Need Help Selecting UDG/dUTP Carryover Prevention Enzymes?
Share your target, sample type, workflow, detection chemistry, instrument, desired reagent format, current formulation, performance goals, and expected scale with our technical team.
Request Product Selection Support
Q1. Does UDG destroy all DNA contamination?
Q2. Why must dUTP be included?
Q3. What is the advantage of heat-labile UDG?
Q4. Can UDG prevent contamination during the same run?
Q5. Will every polymerase work with dUTP?
Q6. How should efficacy be tested?
